Consano Bio

Consano Bio, Inc.

18 Investors

Orthopedic Biologic Therapeutics

BURLINGTON, MA

Consano Bio is an early-stage biotechnology startup founded in 2022 and headquartered in Des Moines, Iowa. The company focuses on developing first-in-category biologic therapeutics to treat painful and debilitating orthopedic conditions. Its core strategy is to target the underlying drivers of disease rather than merely addressing symptoms.

Products & Team

C-1101

Biologic TherapeuticSeed

C-1101 is an allogenic, multi-protein therapeutic currently in development. It is engineered to treat orthopedic injuries by modulating the local environment to favor healing and tissue regeneration.

Value Proposition

C-1101 addresses the root causes of pain and debilitation from orthopedic injuries by actively promoting tissue repair and reducing inflammation, offering a potential alternative to treatments that only manage symptoms.

Pain Points

Patients experience painful and debilitating orthopedic injuries that are not adequately resolved by existing treatments. Current options may only offer symptomatic relief without addressing the underlying tissue damage and inflammation that hinders recovery.

Utilizes potent cytokines to shift the microenvironment from a pro-inflammatory to an anti-inflammatory state.Establishes a protein matrix to provide a scaffold for local cell proliferation.Leverages platelet growth factors to stimulate healing processes directly at the site of injury.